Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Verrica Pharmaceuticals Announced the FDA Granted YCANTHTM New Chemical Entity Status and Orange Book Listing

We are currently working to bring into the upcoming ProhostBiotech Letter some small clinical and commercial innovating firms that are challenging the Top-Tier firms that are currently generating billions of dollars in selling revenues. These firms are developers of products...

March 28, 2024

Amgen: Positive Results from Otezla® Phase 3 DISCREET Study in Moderate to Severe Genital Psoriasis

Amgen Announces Positive Results from Otezla Study for Psoriasis Amgen ( AMGN ) announced positive top-line results from the DISCREET trial - a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla® (apremilast) in adults with moderate...

December 2, 2021

Syndax Pharmaceuticals: Positive Pediatric Data from Pivotal Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals in the NEWS Yesterday, Syndax Pharmaceuticals (NASDAQ: SNDX ) announced the presentation of positive data from the pivotal AUGMENT-101 trial in pediatric patients with relapsed/refractory ( R/R ) KMT2A-rearranged ( KMT2Ar ) acute myeloid leukemia ( AML )...

April 9, 2024

Eli Lilly Gene Therapy Restores Patient Hearing

Akous Inc to Present at the Association for Research in Otolaryngology Akouos, Inc. - a wholly owned subsidiary of Eli Lilly and Company ( LLY ) announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which restored the...

January 24, 2024

Answers About Vertex Pharmaceuticals Acquisition of Alpine Immune. See Also: Important News from Coya Therapeutics on ALS

Vertex Pharmaceuticals Acquisition of Alpine Immune Sciences We start this posting by answering a question by savvy investors regarding Vertex Pharmaceuticals' ( VRTX ) decision to acquire Alpine Immune Sciences ( ALPN ) . The reason for the question is...

April 11, 2024

Ionis Pharmaceuticals to Collaborate with AstraZeneca in Treating Transthyretin Amyloidosis with Ionis Product Eplontersen

Ionis Pharmaceuticals and AstraZeneca in Collaboration to Treat ATTR with Eplontersen Ionis Pharmaceuticals ( IONS ) announced entering into a strategic collaboration agreement with AstraZeneca ( AZN ) to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of...

December 8, 2021

Voyager Therapeutics: Demonstrating Productivity in Collaboration with Neurocrine to Advance Gene Therapies for Neurological Diseases

Voyager Therapeutics Voyager Therapeutics ( VYGR ) is a biotech company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. The firm’s pipeline includes programs for Alzheimer’s disease, amyotrophic...

April 17, 2024

Apellis Announces Negative CHMP Opinion on Pegcetacoplan for GA in the EU and Its Plans to Seek Re-Examination of Application

Apellis Pharmaceuticals Negative CHMP Opinion Apellis Pharmaceuticals ( APLS ) announced that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency has adopted a negative opinion on the marketing authorization application ( MAA...

January 27, 2024

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in the New England Journal of Medicine

Intellia Therapeutics in the NEWS Yesterday, January 31, Intellia Therapeutics ( NTLA ) announced that the results from Phase 1 portion of the Phase 1/2 study of NTLA-2002 were published online in the New England Journal of Medicine ( NEJM...

February 1, 2024

Vertex and TreeFrog Therapeutics Announced Licensing Agreement and Collaboration to Optimize Production of Vertex Cell Therapies for Type 1 Diabetes

Vertex Pharmaceuticals and TreeFrog Therapeutics in the NEWS Vertex Pharmaceuticals ( VRTX ) and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex’s cell therapies for Type...

April 25, 2024

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024